Nexthera Capital »

Intra Cellular Therapies shares owned by Nexthera Capital

Quarter-by-quarter ownership of Intra Cellular Therapies (ITCI) shares owned by Nexthera Capital from 13F filings

Historical chart of Nexthera Capital investment in Intra Cellular Therapies

Tip: Access up to 7 years of quarterly data

All positions including Intra Cellular Therapies held by Nexthera Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Intra Cellular Therapies by Nexthera Capital

Quarter filed Position value Share count Share price at filing
2019-06-30 $1.9M 144k 12.98

More positions owned by Nexthera Capital

Intercept Pharmaceuticals In
Insmed (INSM)
Audentes Therapeutics
Neurocrine Biosciences (NBIX)
Sarepta Therapeutics (SRPT)
Global Blood Therapeutics In
Immunomedics
Coherus Biosciences (CHRS)
Ascendis Pharma A S (ASND)
Pacira Pharmaceuticals (PCRX)
Urogen Pharma (URGN)
Uniqure Nv (QURE)
Amarin Corporation (AMRN)
Abbvie (ABBV)
Biohaven Pharmaceutical Holding

View all positions for Nexthera Capital

Top funds holding Intra Cellular Therapies

Vanguard Group
Daniel D. Thurber
Bellevue Group
venBio Select Advisor
Jpmorgan Chase & Co
Alliancebernstein
Franklin Resources
Wellington Management Company
Jennifer Ranahan
ClearBridge Advisors
Holocene Advisors
T. Rowe Price Associates
Norges Bank Investment Management
Charles Schwab Investment Management
Lord, Abbett & Co

View all funds holding Intra Cellular Therapies